Dayspring Pharma's CG2001 Foam Shows 50% Efficacy Improvement in Phase II Androgenetic Alopecia Trial
Key Insights
Dayspring Pharma (search)'s Phase II trial of CG2001 foam met its primary endpoint in 110 Chinese men with androgenetic alopecia (search), demonstrating statistically significant and clinically meaningful results.
The optimal dosing regimen of 5% minoxidil plus 0.075% finasteride twice daily showed approximately 50% efficacy improvement compared to existing Chinese minoxidil foam studies.
CG2001 demonstrated rapid onset of action, surpassing peak efficacy of comparator studies by Week 12, with excellent safety profile and extremely low systemic exposure.
Dayspring Pharma (search) announced positive top-line results from its Phase II clinical trial of CG2001 foam, a novel topical combination therapy for androgenetic alopecia (search) (AGA (search)) in male patients. The multicenter, randomized, double-blind, placebo-controlled study met its primary endpoint and demonstrated statistically significant and clinically meaningful results with a favorable safety profile.
Trial Design and Patient Population
The 30-week Phase II study enrolled 110 Chinese adult men with AGA (search) and was led by Peking University People's Hospital. The trial was designed to evaluate the efficacy of CG2001 and identify the recommended dosing regimen for Phase III development.
Efficacy Results Exceed Expectations
All CG2001 treatment groups demonstrated markedly superior improvement compared to the placebo group at Week 24. The group receiving 5% minoxidil plus 0.075% finasteride twice daily showed the best efficacy profile. When compared with other registered clinical data, including published data from existing Chinese minoxidil foam studies, CG2001 demonstrated approximately 50% improvement in efficacy.
The treatment also showed rapid onset of action, surpassing the peak efficacy reported in comparator studies as early as Week 12. This accelerated timeline represents a significant advantage over existing therapies in the hair loss treatment landscape.
Safety Profile Demonstrates Low Systemic Exposure
CG2001 was well tolerated throughout the study period and exhibited extremely low systemic exposure. All adverse reactions observed during the study were mild in nature, primarily consisting of pruritus and increased scaliness. These reactions resolved spontaneously without requiring medical intervention.
Novel Formulation Approach
CG2001 represents a topical combination of minoxidil and finasteride designed to harness the synergistic potential of two cornerstone therapies for androgenetic alopecia (search). Minoxidil promotes hair growth, while finasteride inhibits 5α-reductase (search) and reduces dihydrotestosterone (DHT) levels. Both compounds are widely recognized as first-line treatments for male pattern hair loss (search).
The drug is formulated as a specifically designed foam with an optimized dose ratio and delivery system to improve local follicular delivery, enhance efficacy, and minimize systemic exposure associated with oral finasteride administration.
Development Timeline and Future Plans
Based on the overall Phase II results demonstrating strong potential in efficacy, rapid onset of action, and safety, Dayspring Pharma (search) will advance CG2001 into Phase III clinical development. The company plans to further accelerate its research and translational efforts in hair health, aiming to provide patients with more effective and accessible treatment options for androgenetic alopecia (search).